Old drug, new hope: lenalidomide tackles rare histiocyte cancers
NCT ID NCT02523040
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase 2 study tests the chemotherapy drug lenalidomide (Revlimid) in 12 adults with one of three rare histiocyte disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma. The goal is to see how many patients achieve disease control or remission. The trial is no longer recruiting but is still analyzing results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide (Revlimid)
What this could lead to
If it works, this could point toward a new treatment option for rare histiocyte disorders that are hard to treat.
What could go wrong
This is a very small, early-phase trial with only 12 participants, so results may not apply broadly. Lenalidomide is a chemotherapy drug and can cause side effects like low blood counts and fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.